Champions Oncology, Inc. (CSBR) stock
Close on Nov 11, 2026Market cap $66.53MP/E –Yield –
Champions Oncology, Inc. grew revenue 6.7% to $60.66M over the twelve months to Jul 31, 2026. Operating income fell 137.9% to -$1.02M, moving the operating margin from 4.7% to -1.7%. Free cash flow was -$6.14M, down 184.8% from a year earlier. At the latest close the market valued the company at $66.53M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- $66.53M
- P/E ratio
- –
- Price to sales
- 1.10
- Price to book
- 17.09
- Dividend yield
- –
- Free cash flow yield
- -9.22%
Fundamentals
- Revenue
- $60.66M
- Net income
- -$1.10M
- EPS, diluted
- -$0.08
- Free cash flow
- -$6.14M
- Book value per share
- $0.28
- Diluted shares
- 14M
Trading
- Next earnings
- Dec 14, 2026 (estimated, after the close)
- Previous close
- $4.75
- Open
- $4.79
- Day's range
- $4.64 – $4.81
- Volume
- 9,353
- Average volume (20 days)
- 8,029
- Beta (5 years)
- 0.36
- 52-week range
- $4.59 – $8.31
- RSI (14 days)
- 46.2
- Volatility (1 year)
- 53.4%
- Relative volume
- 0.90×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CSBR | S&P 500 | Difference | CSBR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.2% | -2.4% | +1.2 pts | ||
| 3 months | -4.2% | -1.2% | −3.1 pts | ||
| Year to date | -30.8% | +12.3% | −43.1 pts | ||
| 1 year | -31.7% | +12.4% | −44.2 pts | ||
| 3 years | -14.3% | +78.8% | −93.1 pts | -5.0% | +21.4% |
| 5 years | -52.8% | +75.2% | −127.9 pts | -13.9% | +11.9% |
| 10 years | +167.0% | +311.1% | −144.1 pts | +10.3% | +15.2% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Champions Oncology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Champions Oncology
Biological Products, (No Diagnostic Substances)
Champions Oncology, Inc. is a technology-enabled research company that develops computational and experimental platforms to assist in oncology drug discovery and development. The company operates through core business activities that include providing translational research services, licensing proprietary oncology data, and offering software subscriptions. Its offerings feature preclinical pharmacology studies using an extensive bank of patient-derived xenograft models, target discovery services, and Lumin Bioinformatics, a software-as-a-service analytical tool. Champions Oncology primarily serves biotechnology and pharmaceutical companies, as well as cancer research scientists, seeking to identify therapeutic targets and evaluate experimental treatments.
Company profile, executives and historyChampions Oncology stock: common questions
What is Champions Oncology's stock price?
CSBR closed at $4.78 on Nov 11, 2026, up 0.63% on the day. Over the past 52 weeks it traded between $4.59 and $8.31.
What is Champions Oncology's market cap?
Champions Oncology was worth $66.53M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CSBR's P/E ratio?
Champions Oncology lost money over the twelve months to Jul 31, 2026 (diluted EPS -$0.08), so it has no meaningful P/E ratio.
How much revenue does Champions Oncology make?
Champions Oncology reported revenue of $60.66M for the twelve months to Jul 31, 2026, up 6.7% from a year earlier.
Does Champions Oncology pay a dividend?
No. Champions Oncology has not paid a cash dividend over the last twelve months.
When does Champions Oncology report earnings next?
Champions Oncology is expected to report Q2 FY2027 results on Dec 14, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CSBR stock performed over the past year?
Including dividends, CSBR returned -31.7% over the past year, against +12.4% for the S&P 500.
How many CSBR shares are sold short?
0M shares were sold short at the latest FINRA report, 0.75% of the float, or 8.6 days of average trading volume.
Who are Champions Oncology's competitors?
Companies most similar to Champions Oncology by business, industry and size include CGEN, RXRX, STRO, BDTX, ADAPY.
See a number that looks wrong?